Stock Rating Report for ALKS
|
|
Stock Information
| Ticker |
ALKS |
| Company Name |
Alkermes plc |
| Current Price |
$19.26 |
| Previous Close |
$19.26 |
| Industry |
Drug Delivery |
| Sector |
HEALTHCARE |
| Long Stop Loss |
Members Only |
| Short Stop Loss |
Members Only |
| Expected Move |
Members Only |
| Optionable? |
Yes
|
StockProphet Ratings
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
Sector Risks
Chart
We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for ALKS. However, we only show it to our subscribers.
We update our ratings and stop losses EVERY WEEK.
Don't miss out on what we recommend for Alkermes plc next week. Sign up today and start making money!
Demand Fundamentals
|
Demand Technicals
Company Profile
Alkermes plc, an integrated biotechnology company, develops medicines that enhance patient outcomes. The company has a diversified portfolio of approximately 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as addiction, schizophrenia, and depression. It manufactures and commercializes VIVITROL for alcohol and opioid dependence- and manufactures RISPERDAL CONSTA for schizophrenia and bipolar I disorder. Alkermes' pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction, and diabetes. The company was founded in 1987 and headquartered in Dublin, Ireland.
|
Latest News
| Tue, 07 Feb 2012 19:03:37 GMT | Take the Long Road with Alkermes | | Tue, 07 Feb 2012 07:36:40 GMT | Top Q4 Buys And Sells Of Healthcare-Focused Hambrecht And Quist Capital Management | | Mon, 06 Feb 2012 21:00:00 GMT | Alkermes? Corporate Presentation to be Webcast at the 14th Annual BIO CEO & Investor Conference | | Mon, 06 Feb 2012 14:30:22 GMT | Novo Nordisk Posts Solid 4Q | | Mon, 06 Feb 2012 14:17:46 GMT | Alkermes Beats Up on Analysts Yet Again | | Mon, 06 Feb 2012 13:21:58 GMT | The Curse of Amylin's Diabetes Drug Approval | | Mon, 06 Feb 2012 11:25:55 GMT | The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and Eli Lilly & Company | | Sun, 05 Feb 2012 14:20:53 GMT | New Star Analyst Rankings for Alkermes plc | | Sun, 05 Feb 2012 10:10:10 GMT | Friday's Noteworthy Insider Buys And Sells In The Technology And Healthcare Sectors | | Fri, 03 Feb 2012 21:16:21 GMT | U.S. Companies Issuing Profit Outlooks for the Week of Feb. 3 | | Fri, 03 Feb 2012 15:15:23 GMT | Revenues Skyrocket at Merged Alkermes | | Fri, 03 Feb 2012 15:07:20 GMT | Has Elan Become the Perfect Stock? | | Fri, 03 Feb 2012 09:09:48 GMT | Amylin Pharmaceuticals: There Are Better Investment Opportunities In Biotech | | Thu, 02 Feb 2012 22:54:46 GMT | Drugmaker Alkermes fiscal 3Q loss widens | | Thu, 02 Feb 2012 21:52:29 GMT | U.S. Companies Issuing Profit Outlooks for Feb. 2 | | Thu, 02 Feb 2012 12:17:53 GMT | ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits | | Thu, 02 Feb 2012 12:07:21 GMT | Q3 2012 Alkermes plc Earnings Release - Time Not Supplied | | Thu, 02 Feb 2012 12:00:00 GMT | Alkermes plc Reports Third Quarter Fiscal 2012 Financial Results | | Thu, 02 Feb 2012 03:52:00 GMT | Drugmakers Upset Approval System Plan Biotechs Sought | | Wed, 01 Feb 2012 21:21:56 GMT | [$$] What Do the Stock Charts Suggest for February? | News provided by Yahoo! Finance |
|
|
|
|
